Neuroderm Ltd Ord Sh (NDRM) 17.38 $NDRM
NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
GlobeNewswire - Mon Sep 19, 8:28AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that the Company will present previously unreported human factors data from a usability study focused on the interactions between Parkinson's disease patients and the mini-pump device used to administer ND0612, the Company's continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation. The data will be presented at the 4 World Parkinson Congress (WPC) taking place in Portland, Oregon, on September 20-23.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Aug 25, 6:25AM CDT
NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.
NDRM: 17.38 (+0.09)
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson's Disease
GlobeNewswire - Thu Aug 25, 6:18AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company's low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation.
NDRM: 17.38 (+0.09)
NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
GlobeNewswire - Thu Aug 11, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the second quarter of 2016 before the market opens on Thursday, August 25, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
NDRM: 17.38 (+0.09)
NeuroDerm (NDRM) Looks Good: Stock Adds 5.1% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:40AM CDT
NeuroDerm Ltd. (NDRM) saw its shares rise above 5% in the last trading session.
JNP: 5.92 (+0.08), NDRM: 17.38 (+0.09)
NeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7
GlobeNewswire - Tue May 31, 1:11PM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, at 2:30pm ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
NDRM: 17.38 (+0.09)
NeuroDerm Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 26, 6:32AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2016.
NDRM: 17.38 (+0.09)
NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016
GlobeNewswire - Tue May 17, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the first quarter of 2016 before the market opens on Thursday, May 26, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson's Disease
GlobeNewswire - Mon May 09, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company's continuously administered subcutaneous levodopa/carbidopa (LD/CD) formulation used in both ND0612H and ND0612L.
NDRM: 17.38 (+0.09)
NeuroDerm Announces 2016 Annual General Meeting of Shareholders
GlobeNewswire - Thu May 05, 9:13AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 2016 Annual General Meeting of Shareholders on Tuesday, June 14, 2016 for the purposes of (i) re-electing its Class II directors, Shmuel Cabilly and Larry Ellberger, for a three-year term, (ii) ratifying the re-appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for 2016 and until the Company's next annual general meeting of shareholders and authorization of the Company's Board of Directors, with power of delegation to its audit committee, to set the fees to be paid to such auditors, (iii) approving a grant of options to, and an increase in the salary of, the Company's Chief Executive Officer, Dr. Oded Lieberman, and (iv) approving an increase in the annual director fees of the Company's director Larry Ellberger. The record date for shareholders entitled to vote at the meeting is Monday, May 9, 2016. Each of the proposals for the shareholders meeting has been approved by the appropriate committee of the Company's Board of Directors and by the Board, and is being brought before the shareholders for approval pursuant to requirements under the Israeli Companies Law.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials
GlobeNewswire - Fri Apr 22, 8:30AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the Company has been informed by Cane S.p.A., the third party manufacturer of the infusion pumps used to deliver ND0612 in its current clinical trials, that they have been removed from the list of companies under import alert. This latest regulatory action by the U. S. Food and Drug Administration (FDA), dated April 21, 2016, means that normal shipments to the US of devices from this manufacturer can now be resumed.
NDRM: 17.38 (+0.09)
Holding the Course, Oculus Innovative Sciences Delivers Revenue Growth Again
ACCESSWIRE - Tue Feb 09, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 9, 2016 / 2016 has been brutal for many sectors, but perhaps none so much as for biotechnology and pharmaceutical companies. For instance, the Nasdaq Biotechnology Index has been clubbed from 3,550 at the end of December to around 2,550, for a loss of roughly 28 percent. A wider view shows that this sector has been languishing since NBI hit an all-time high of 4,195 in July 2015. Given a $200 million market cap minimum for the index, components are diverse in size, ranging from a giant like Celgene (NASDAQ: CELG) to much smaller companies, such as NeuroDerm (NASDAQ: NDRM) and Flexion Therapeutics (NASDAQ: FLXN), demonstrating how broad the sell-off has been.
FLXN: 17.12 (+0.36), OCLS: 4.17 (+0.02), NDRM: 17.38 (+0.09), CELG: 108.49 (+0.76), CELGZ: 1.21 (+0.01)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.52 (-0.10), MDGN: 5.50 (+0.21), ADHD: 4.60 (+0.05), SUPN: 25.73 (+0.82), COLL: 11.46 (+0.93), DRRX: 1.73 (+0.05), NEOS: 7.43 (-0.12), NDRM: 17.38 (+0.09), MRK: 62.17 (+0.84), SHPG: 206.48 (+3.04), ITCI: 44.02 (-0.12)
NeuroDerm CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 14, 2016
GlobeNewswire - Mon Jan 04, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:00am PT in San Francisco. Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
JPM: 66.30 (+0.11), NDRM: 17.38 (+0.09)
NeuroDerm Begins Enrollment in Parkinson's Disease Study
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 9:00AM CST
NeuroDerm (NDRM) has started patient enrollment in a phase II study on ND0612H for the treatment of advanced Parkinson's disease patients.
AERI: 38.22 (+4.10), ABBV: 63.30 (+0.39), PRTA: 61.93 (+0.83), NDRM: 17.38 (+0.09)
NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson's Disease
GlobeNewswire - Wed Dec 30, 6:08AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the company's continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments for patients with advanced Parkinson's disease that require surgical intervention. The multicenter international phase II clinical study will compare the efficacy, safety and tolerability of ND0612H to the baseline oral standard of care. ND0612H, administered through a belt pump, is designed to deliver steady LD/CD levels and improve motor fluctuations that cannot be adequately controlled with oral therapy and might otherwise require surgical intervention.
NDRM: 17.38 (+0.09)
NeuroDerm Added to the Nasdaq Biotechnology Index
GlobeNewswire - Fri Dec 18, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the company has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 21, 2015.
NDRM: 17.38 (+0.09)
Why NeuroDerm Ltd. (NDRM) Might Be a Diamond in the Rough
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 7:37AM CST
NeuroDerm Ltd. (NDRM) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
NDRM: 17.38 (+0.09)
Analyst Insights Behind Price Movement - Research on Ashford Hospitality Prime, Neuroderm, NN, and Roadrunner Transportation Systems
ACCESSWIRE - Wed Nov 25, 7:39AM CST
NEW YORK, NY / ACCESSWIRE / November 25, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Ashford Hospitality Prime Inc (NYSE: AHP), Neuroderm Ltd (NASDAQ: NDRM), NN Inc (NASDAQ: NNBR) and Roadrunner Transportation Systems (NYSE: RRTS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
RRTS: 7.90 (-0.30), AHP: 14.43 (+0.08), NNBR: 17.62 (-0.11), NDRM: 17.38 (+0.09)
Should NeuroDerm (NDRM) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Thu Nov 19, 7:57AM CST
NeuroDerm has actually seen loss estimates narrow over the past month for the current fiscal, and looks well positioned for a solid gain
NDRM: 17.38 (+0.09)
NeuroDerm to Present ND0612 Data at 4th World Parkinson Congress Demonstrating Ease of Use of Mini-Pump Delivery System
GlobeNewswire - Mon Sep 19, 8:28AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that the Company will present previously unreported human factors data from a usability study focused on the interactions between Parkinson's disease patients and the mini-pump device used to administer ND0612, the Company's continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation. The data will be presented at the 4 World Parkinson Congress (WPC) taking place in Portland, Oregon, on September 20-23.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Aug 25, 6:25AM CDT
NeuroDerm Ltd. (NASDAQ:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.
NDRM: 17.38 (+0.09)
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson's Disease
GlobeNewswire - Thu Aug 25, 6:18AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the company's low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation.
NDRM: 17.38 (+0.09)
NeuroDerm to Host Second Quarter 2016 Financial Results Conference Call on August 25, 2016
GlobeNewswire - Thu Aug 11, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the second quarter of 2016 before the market opens on Thursday, August 25, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
NDRM: 17.38 (+0.09)
NeuroDerm (NDRM) Looks Good: Stock Adds 5.1% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jun 07, 7:40AM CDT
NeuroDerm Ltd. (NDRM) saw its shares rise above 5% in the last trading session.
JNP: 5.92 (+0.08), NDRM: 17.38 (+0.09)
NeuroDerm CEO to Present at Jefferies 2016 Healthcare Conference on June 7
GlobeNewswire - Tue May 31, 1:11PM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies 2016 Healthcare Conference on Tuesday, June 7, at 2:30pm ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's next-generation treatments for central nervous system disorders, including the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
NDRM: 17.38 (+0.09)
NeuroDerm Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 26, 6:32AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the first quarter ended March 31, 2016.
NDRM: 17.38 (+0.09)
NeuroDerm to Host First Quarter 2016 Financial Results Conference Call on May 26, 2016
GlobeNewswire - Tue May 17, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will report financial results for the first quarter of 2016 before the market opens on Thursday, May 26, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Patient Enrollment in Long-Term Safety Trial of ND0612 for Parkinson's Disease
GlobeNewswire - Mon May 09, 6:00AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company's continuously administered subcutaneous levodopa/carbidopa (LD/CD) formulation used in both ND0612H and ND0612L.
NDRM: 17.38 (+0.09)
NeuroDerm Announces 2016 Annual General Meeting of Shareholders
GlobeNewswire - Thu May 05, 9:13AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it will hold its 2016 Annual General Meeting of Shareholders on Tuesday, June 14, 2016 for the purposes of (i) re-electing its Class II directors, Shmuel Cabilly and Larry Ellberger, for a three-year term, (ii) ratifying the re-appointment of Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as the Company's independent registered public accounting firm for 2016 and until the Company's next annual general meeting of shareholders and authorization of the Company's Board of Directors, with power of delegation to its audit committee, to set the fees to be paid to such auditors, (iii) approving a grant of options to, and an increase in the salary of, the Company's Chief Executive Officer, Dr. Oded Lieberman, and (iv) approving an increase in the annual director fees of the Company's director Larry Ellberger. The record date for shareholders entitled to vote at the meeting is Monday, May 9, 2016. Each of the proposals for the shareholders meeting has been approved by the appropriate committee of the Company's Board of Directors and by the Board, and is being brought before the shareholders for approval pursuant to requirements under the Israeli Companies Law.
NDRM: 17.38 (+0.09)
NeuroDerm Announces Removal of FDA Import Alert of Infusion Pumps Used in ND0612 Clinical Trials
GlobeNewswire - Fri Apr 22, 8:30AM CDT
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the Company has been informed by Cane S.p.A., the third party manufacturer of the infusion pumps used to deliver ND0612 in its current clinical trials, that they have been removed from the list of companies under import alert. This latest regulatory action by the U. S. Food and Drug Administration (FDA), dated April 21, 2016, means that normal shipments to the US of devices from this manufacturer can now be resumed.
NDRM: 17.38 (+0.09)
Holding the Course, Oculus Innovative Sciences Delivers Revenue Growth Again
ACCESSWIRE - Tue Feb 09, 8:25AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 9, 2016 / 2016 has been brutal for many sectors, but perhaps none so much as for biotechnology and pharmaceutical companies. For instance, the Nasdaq Biotechnology Index has been clubbed from 3,550 at the end of December to around 2,550, for a loss of roughly 28 percent. A wider view shows that this sector has been languishing since NBI hit an all-time high of 4,195 in July 2015. Given a $200 million market cap minimum for the index, components are diverse in size, ranging from a giant like Celgene (NASDAQ: CELG) to much smaller companies, such as NeuroDerm (NASDAQ: NDRM) and Flexion Therapeutics (NASDAQ: FLXN), demonstrating how broad the sell-off has been.
FLXN: 17.12 (+0.36), OCLS: 4.17 (+0.02), NDRM: 17.38 (+0.09), CELG: 108.49 (+0.76), CELGZ: 1.21 (+0.01)
Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxcczv/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Attention Deficit Hyperactivity Disorder (ADHD) Overview - Therapeutics Development - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Overview - Pipeline Products for Attention Deficit Hyperactivity Disorder (ADHD) - Comparative Analysis - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Therapeutics under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Development by Companies - Attention Deficit Hyperactivity Disorder (ADHD) - Products under Investigation by Universities/Institutes - Attention Deficit Hyperactivity Disorder (ADHD) - Companies Involved in Therapeutics Development - Alcobra Ltd - Amarantus Bioscience Holdings, Inc. - APeT Holding BV - Arbor Pharmaceuticals, LLC. - BCWorld Pharm Co. Ltd. - Collegium Pharmaceutical, Inc. - Curemark, LLC - Domain Therapeutics SA - DURECT Corporation - H. Lundbeck A/S - Heptares Therapeutics Limited - Highland Therapeutics, Inc. - Hisamitsu Pharmaceutical Co., Inc. - Integrative Research Laboratories Sweden AB - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Luc Therapeutics, Inc. - Medgenics Inc. - Merck & Co., Inc. - Neos Therapeutics, Inc. - NeuroDerm Ltd. - Neurovance, Inc. - P2D Bioscience - Polleo Pharma Limited - Reviva Pharmaceuticals Inc. - Samyang Biopharmaceuticals Corporation - Shire Plc - Signature Therapeutics, Inc - Sunovion Pharmaceuticals Inc. - Supernus Pharmaceuticals, Inc. - Taisho Pharmaceutical Holdings Co., Ltd. - Tris Pharma, Inc. - Vernalis Plc For more information visit http://www.researchandmarkets.com/research/jx...on_deficit
KMPH: 4.52 (-0.10), MDGN: 5.50 (+0.21), ADHD: 4.60 (+0.05), SUPN: 25.73 (+0.82), COLL: 11.46 (+0.93), DRRX: 1.73 (+0.05), NEOS: 7.43 (-0.12), NDRM: 17.38 (+0.09), MRK: 62.17 (+0.84), SHPG: 206.48 (+3.04), ITCI: 44.02 (-0.12)
NeuroDerm CEO to Present at the 34th Annual J.P. Morgan Healthcare Conference on January 14, 2016
GlobeNewswire - Mon Jan 04, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that CEO Oded S. Lieberman, PhD will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:00am PT in San Francisco. Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
JPM: 66.30 (+0.11), NDRM: 17.38 (+0.09)
NeuroDerm Begins Enrollment in Parkinson's Disease Study
Zacks Equity Research - Zacks Investment Research - Thu Dec 31, 9:00AM CST
NeuroDerm (NDRM) has started patient enrollment in a phase II study on ND0612H for the treatment of advanced Parkinson's disease patients.
AERI: 38.22 (+4.10), ABBV: 63.30 (+0.39), PRTA: 61.93 (+0.83), NDRM: 17.38 (+0.09)
NeuroDerm Announces Start of Patient Enrollment in Phase II Trial of ND0612H for Advanced Parkinson's Disease
GlobeNewswire - Wed Dec 30, 6:08AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced the start of patient enrollment in a first efficacy trial of ND0612H, the company's continuously administered subcutaneous levodopa/carbidopa solution. This treatment is intended to be an alternative to current treatments for patients with advanced Parkinson's disease that require surgical intervention. The multicenter international phase II clinical study will compare the efficacy, safety and tolerability of ND0612H to the baseline oral standard of care. ND0612H, administered through a belt pump, is designed to deliver steady LD/CD levels and improve motor fluctuations that cannot be adequately controlled with oral therapy and might otherwise require surgical intervention.
NDRM: 17.38 (+0.09)
NeuroDerm Added to the Nasdaq Biotechnology Index
GlobeNewswire - Fri Dec 18, 6:00AM CST
NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that the company has been selected for addition to the Nasdaq Biotechnology Index (Nasdaq:NBI), effective December 21, 2015.
NDRM: 17.38 (+0.09)
Why NeuroDerm Ltd. (NDRM) Might Be a Diamond in the Rough
Zacks Equity Research - Zacks Investment Research - Thu Dec 03, 7:37AM CST
NeuroDerm Ltd. (NDRM) sees solid earnings estimate revisions and looks poised to shock the market, and yet seems overlooked by the investors.
NDRM: 17.38 (+0.09)
Analyst Insights Behind Price Movement - Research on Ashford Hospitality Prime, Neuroderm, NN, and Roadrunner Transportation Systems
ACCESSWIRE - Wed Nov 25, 7:39AM CST
NEW YORK, NY / ACCESSWIRE / November 25, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Ashford Hospitality Prime Inc (NYSE: AHP), Neuroderm Ltd (NASDAQ: NDRM), NN Inc (NASDAQ: NNBR) and Roadrunner Transportation Systems (NYSE: RRTS). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
RRTS: 7.90 (-0.30), AHP: 14.43 (+0.08), NNBR: 17.62 (-0.11), NDRM: 17.38 (+0.09)
Should NeuroDerm (NDRM) Be On Your Radar Now?
Zacks Equity Research - Zacks Investment Research - Thu Nov 19, 7:57AM CST
NeuroDerm has actually seen loss estimates narrow over the past month for the current fiscal, and looks well positioned for a solid gain
NDRM: 17.38 (+0.09)
